Semax International

History and Background


SEMAX® is a neuropeptide developed by the Institute of Molecular Genetics; Russian Academy of Sciences, Moscow, Russia and “Lomonosov” University, Moscow . Research started in 1982 and involved over 30 scientists in the fields of Neurochemistry, Neurobiology, Neurology and Biochemistry from the Russian Federation.

The focus was on a short fragment of ACTH, Pro8-Gly9-Pro10 ACTH(4-10) and by dissociation of the combination of amino acids, substitution and special linkages a peptide was synthesized which had unique neuroregulatory properties.
Extensive testing over a period of 14 years resulted in the approval of the Russian Federation Ministry of Public Health and Pharmaceutical Industry on 28 March, 1996, for the clinical use of SEMAX® in the Russian Federation as a neuroactive peptide with endogenous regulatory properties affecting cerebral cellular processes which are beneficial in protecting and enhancing the recovery of cerebral functions after ischemic insults like : brain stroke, closed head injuries. Neurodegenerative processes like in Alzheimer’s disease, Parkinson’s disease and Huntington’s Chorea.

SEMAX® also influences the intellectual capacities and memory as well as concentration of normal, healthy persons subjected to stressful working conditions, increasing their mental capacities and diminishing the index of workload.


Copyright © 2003-2008 Semax International Inc. All Rights Reserved. Design Hoover